文献速递结核与非结核分枝杆菌

高血压与钙通道阻滞剂对结核病治疗结局的影响

The Impact of Hypertension and Use of Calcium Channel Blockers on Tuberculosis Treatment Outcomes.
PubMed 文献 · Clin Infect Dis · 2021-01-01

这项回顾性队列研究纳入2000至2016年台湾大学医院2894例培养确诊药物敏感结核病成人患者,评估高血压与钙通道阻滞剂使用与治疗前9个月全因及感染相关死亡率、2和6个月痰涂片及培养阳性的关联。结果显示高血压与全因死亡(HR 1.57)和感染相关死亡(HR 1.87)风险升高相关,二氢吡啶类钙通道阻滞剂使用仅与全因死亡降低相关(HR 0.67),但微生物学结局无显著差异。

要点

  • 高血压与结核治疗9个月内全因及感染相关死亡风险升高独立相关。
  • 二氢吡啶类钙通道阻滞剂使用可能与全因死亡降低相关,但证据有限。
  • 高血压或钙通道阻滞剂使用未显著改变2和6个月微生物学结局。

核心结论

  • 高血压患者在接受结核治疗后的9个月内全因死亡和感染相关死亡风险增加。
  • 二氢吡啶类钙通道阻滞剂使用可能降低高血压结核患者的全因死亡率。
  • 高血压或钙通道阻滞剂使用未导致微生物学结局的显著变化。

研究设计与样本

  • 回顾性队列研究,纳入2000至2016年台湾大学医院所有18岁以上接受培养确诊药物敏感结核治疗的患者,共2894例。

主要发现

  • 2894例患者中1052例(36.4%)患有高血压。
  • 多变量分析显示高血压与全因死亡风险升高相关(HR 1.57;95%CI 1.23-1.99)。
  • 高血压与感染相关死亡风险升高相关(HR 1.87;95%CI 1.34-2.6)。
  • 按高血压分组,微生物学结局无统计学差异。

临床怎么用

  • 对合并高血压的结核病患者应加强死亡风险评估与监测。
  • 二氢吡啶类钙通道阻滞剂对全因死亡的潜在获益需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertension induces systemic inflammation, but its impact on the outcome of infectious diseases like tuberculosis (TB) is unknown. Calcium channel blockers (CCB) improve TB treatment outcomes in preclinical models, but their effect in patients with TB remain unclear. METHODS: This retrospective cohort study, including all patients > 18 years receiving treatment for culture-confirmed, drug-sensitive TB from 2000 to 2016 at the National Taiwan University Hospital, assessed the association of hypertension and CCB use with all-cause and infection-related mortality during the first 9 months of TB treatment, as well as sputum smear microscopy and sputum culture positivity at 2 and 6 months. RESULTS: Of the 2894 patients, 1052 (36.4%) had hypertension. A multivariable analysis revealed that hypertension was associated with increased mortality due to all causes (hazard ratio [HR], 1.57; 95% confidence interval [CI], 1.23-1.99) and infections (HR, 1.87; 95% CI, 1.34-2.6), but there were no statistical differences in microbiological outcomes when stratified based on hypertensive group. Dihydropyridine-CCB (DHP-CCB) use was associated only with reduced all-cause mortality (HR, 0.67; 95% CI, .45-.98) by univariable Cox regression. There were no associations between DHP-CCB use and infection-related mortality (HR, 0.78; 95% CI, .46-1.34) or microbiological outcomes in univariable or multivariable regression analyses. CONCLUSIONS: Patients with hypertension have increased all-cause mortality and infection-related mortality during the 9 months following TB treatment initiation. DHP-CCB use may lower all-cause mortality in TB patients with hypertension. The presence of hypertension or the use of CCB did not result in a significant change in microbiological outcomes.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Chidambaram V, Gupte A, Wang JY, et al. The Impact of Hypertension and Use of Calcium Channel Blockers on Tuberculosis Treatment Outcomes. Clin Infect Dis. 2021. PMID: 32971534. doi:10.1093/cid/ciaa1446

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。